Global Gold Mining (ASX: GGM) has returned gold recoveries above 91% from metallurgical testwork at its Sturec deposit in Slovakia, using a simplified flotation flowsheet that supports the project's pre-feasibility study.
Healius (ASX: HLS), founded in 1985, has agreed to sell Agilex Biolabs to Novotech for an enterprise value of $160 million, sharpening its focus on core pathology operations.
DroneShield (ASX: DRO) delivered record 1H26 revenue of $125.8M (+74%) and growing recurring software revenue, but margins fell to 60%, costs surged, and a $32.2M statutory loss raises questions on whether earnings can catch up to justify its share price.
Silver Mines (ASX: SVL) has secured a A$70 million placement at 14.5 cents to fund Bowdens approvals and royalty acquisitions, but the roughly 22% share issue and a 14.3% price drop put dilution in focus.
Aeris delivered strong FY26 earnings and cash flow, underpinned by Tritton and Cracow, with no debt. Growth projects support longer-term value, but higher FY27 capital spending and Cracow’s limited reserves create execution risks.
OncoSil Medical is moving into commercial execution after US FDA approval, growing adoption in Spain, fresh institutional funding, and manufacturing progress, with investors watching reimbursement, hospital uptake, and demand.
